GHK-Cu dosage in preclinical studies: concentrations, routes, and durations from the published literature.
GHK-Cu is a research peptide. All dose data on this page is cited from published studies conducted in cell culture, rodent models, or human topical trials. No human administration protocol is presented or recommended.
GHK-Cu Dosage in Preclinical Studies
GHK-Cu has been studied across a concentration range spanning twelve orders of magnitude — from 10⁻¹² M (picomolar, the lowest concentration showing measurable collagen stimulation in fibroblast cultures)[1] to 10⁻⁶ M (micromolar, the upper bound of most in vitro gene-expression studies).[2] The dose-response pattern documented in fibroblast collagen assays is: threshold activity at 10⁻¹² M; maximal stimulation at 10⁻⁹ M (1 nanomolar); the response plateau beginning at 10⁻⁸ M.[1]
| Model | Concentration / Dose | Route | Source |
|---|---|---|---|
| In vitro fibroblast (collagen/ECM) | 1–10 nM (10⁻⁹ to 10⁻⁸ M) | In vitro | [1][4] |
| Gene expression arrays | 10⁻¹² to 10⁻⁶ M | In vitro | [2][7] |
| Human topical skin (12-week) | 0.1–1% in facial cream, daily | Topical | [13][14] |
| Mouse scald wound (liposomal) | Liposomal formulation | Topical | [5] |
| Mouse LPS acute lung injury | Not specified in abstract | Systemic | [6] |
| Mouse intranasal aging model | 15 mg/kg intranasal, 8 weeks | Intranasal | [7] |
| Anti-fibrotic myofibroblast | Dose-dependent range | In vitro | [17] |
GHK-Cu Dosage Protocol in Research Topical Studies
Published topical studies applied GHK-Cu formulations at 0.1–1% concentration once or twice daily to clean skin, typically after cleansing and before heavier moisturizers, for study durations of 8–12 weeks.[13][14] The largest human study (71 women, Pickart et al. 2015) used daily application for 12 weeks.[13] Post-laser application (Miller et al. 2006) used a GHK-Cu skin-care regimen applied immediately post-procedure in a 13-patient RCT.[15]
LIMITATION
Skin penetration note: native GHK-Cu penetrates intact human stratum corneum poorly due to its hydrophilic character and ionic copper center.[19] Liposomal encapsulation has been studied to improve delivery, but as of 2025 there are no standardized analytical methods to quantify how much encapsulated GHK-Cu actually reaches viable skin layers.
Pharmacokinetics: GHK-Cu Half-Life
Formal plasma pharmacokinetic data for GHK-Cu in humans is not available in published peer-reviewed literature. No published study has characterized half-life, volume of distribution, or plasma clearance in human subjects following topical, subcutaneous, or intravenous administration.
For topical application: skin retention after 0.1–1% topical application has not been formally characterized via pharmacokinetic methods in published studies.[19] Liposomal delivery shows promise for enhanced skin penetration but methodological gaps prevent quantification of actual skin-layer concentrations.[19]
What Is the GHK-Cu Half-Life?
Plasma half-life data for GHK-Cu in humans is not available in published literature.[19] In topical studies, retention in skin layers has not been formally characterized via pharmacokinetic methods. No clinical pharmacokinetic study measuring absorption, half-life, or clearance for any route of administration has been completed and published.
Daily vs. Cyclical Dosing in Research Models
Preclinical studies have used both daily and cyclical dosing schedules depending on the application and model. The published topical human studies used daily application over 12-week windows.[13] Animal models vary: acute wound and inflammation studies use single or multi-dose designs; the 8-week intranasal cognitive study used repeated dosing; the anti-fibrotic myofibroblast study used in vitro continuous exposure.
No human consensus dosing protocol exists. Human clinical data is limited to topical cosmetic studies of 8–12 weeks; no dose-finding study for any other route has been published.
Should GHK-Cu Be Taken Daily?
Preclinical studies have used both daily and cyclical dosing schedules depending on the application; no consensus human dosing protocol exists.[13] Published topical studies applied formulations daily over 12-week windows.[13][14] For injectable or systemic use in humans, no dosing study has been published.
Duration of Use in Published Studies
The longest published topical human studies ran 12 weeks.[13][14] No long-term (>6 month) safety or efficacy data exists in peer-reviewed human trials for any route of administration. The 2024 BioImpacts systematic review identifies this duration gap as a critical limitation of the GHK-Cu human evidence base.[14]
How Long Can You Take GHK-Cu Peptide?
The longest published topical studies ran 12 weeks.[13][14] No long-term (>6 month) safety or efficacy data exists in peer-reviewed human trials for systemic administration. The absence of chronic-use safety data is a documented limitation of the current literature.[14]
Formulation Stability and Storage
GHK-Cu is sensitive to strong acids. Low-pH formulations — vitamin C serums at pH <3.5, AHA/BHA peels — can dissociate the copper-peptide complex, reducing the biologically active chelated form.[19] In topical formulations, simultaneous application with strong acids is identified as a stability risk in both the research literature and formulation reviews.
Copper(II) complexation increases the peptide's partition coefficient and enhances membrane permeability compared to the free peptide, which is part of why the chelated form is biologically active in cell culture assays.[1][4]